Swedish Orphan Biovitrum Becomes Market Authorisation Holder For Xiapex In Europe
4/7/2014 8:47:16 AM
Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan
Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL)
today announced that Sobi became the Market Authorisation Holder (MAH) for
Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries,
Norway, and Iceland on 3 April, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by